Dermatology

This site is intended for healthcare professionals only

Login Register

MD Brand Connect
Vaccine Hub
MDTV
Fact Check
Health Dialogues

Medical News & Guidelines
Health news
Fact Check
AYUSH
State News
Medical Education
Industry
MDTV

This site is intended for healthcare professionals only

Login Register

LoginRegister

Home
Medical news & Guidelines
Health news
Fact Check
AYUSH
State News
Medical Education
Industry

Ruchika Sharma

Ruchika Sharma joined Medical Dialogue as an Correspondent for the Business Section in 2019. She covers all the updates in the Pharmaceutical field, Policy, Insurance, Business Healthcare, Medical News, Health News, Pharma News, Healthcare and Investment. She has completed her B.Com from Delhi University and then pursued postgraduation in M.Com. She can be contacted at editorial@medicaldialogues.in Contact no. 011-43720751

Home

Ruchika Sharma

Articles By : Ruchika Sharma

CDSCO releases regulatory guidelines for sampling of drugs, cosmetics and medical devices

Ruchika Sharma19 Feb 2024 6:30 PM IST

New Delhi: In order to streamline and rationalize the sampling procedure of drugs, cosmetics and medical devices and maintaining a centralized monthly...

AstraZeneca, Summit in discussions over USD 15 billion cancer drug licensing deal: Report

AstraZeneca-Daiichi Sankyo application for Datopotamab deruxtecan accepted in US for patients with previously treated advanced nonsquamous non-small cell lung cancer

Ruchika Sharma19 Feb 2024 4:30 PM IST

Cambridge: AstraZeneca and Daiichi Sankyo's Biologics License Application (BLA) for datopotamab deruxtecan (Dato-DXd) has been accepted in the US...

India's stand on intellectual property rights, pharma help promote growth of generic industry: GTRI Report

Ruchika Sharma19 Feb 2024 2:30 PM IST

New Delhi: India's stand on intellectual property rights (IPRs) and pharma issues in proposed trade agreements balances innovation with public health...

Production at Odisha first vaccine manufacturing plant to commence by May

Ruchika Sharma19 Feb 2024 1:30 PM IST

The facility is expected to produce over 15 vaccines for various diseases, including cholera and malaria.

Delhi: DPSRU VC removed over recruitment scam

Ruchika Sharma19 Feb 2024 12:30 PM IST

The LG, the chancellor of the DPSRU, also gave his nod to filing an FIR against Goyal and six other officers named in a report by the three-member...

Should Nutraceuticals be brought under CDSCO? Government forms panel to decide

Ruchika Sharma19 Feb 2024 11:30 AM IST

Officials said due to unsupervised usage of supplements, people at the same time consume supplements along with drugs which might interact with each...

Unichem Labs Roha facility gets 3 USFDA observations

Telangana drug regulator becomes eligible to observe USFDA inspections

Ruchika Sharma18 Feb 2024 11:30 AM IST

The DCA DG said this collaboration could potentially lead to enhanced regulatory harmonisation, improved compliance with global standards, and better...

Sanofi gets USFDA fast track designation for neovascular age-related macular degeneration gene therapy

Sanofi Dupixent gets Japenese nod for chronic spontaneous urticaria

Ruchika Sharma18 Feb 2024 10:00 AM IST

Paris: Sanofi has announced that the Ministry of Health, Labor and Welfare (MHLW) in Japan has granted marketing and manufacturing authorization...

Roche receives EU CE mark for Contivue for neovascular age-related macular degeneration

Roche Xolair gets USFDA nod for children, adults with one or more food allergies

Ruchika Sharma17 Feb 2024 4:30 PM IST

In the U.S., Genentech, a member of the Roche Group, and Novartis Pharmaceuticals Corporation work together to develop and co-promote Xolair.

Gilead Seladelpar gets Conditional European Marketing Authorization for Primary Biliary Cholangitis treatment

Gilead Sciences pauses enrollment globally in magrolimab solid tumor studies

Ruchika Sharma17 Feb 2024 2:43 PM IST

Foster City: Gilead Sciences, Inc. has announced that it has paused enrollment globally in the magrolimab solid tumor studies. The U.S. Food and Drug...

Novartis, Argo Biopharma expand strategic alliance with USD 5.2 billion Cardiovascular drugs deal

Will Novartis continue business in India? Global Drug major strategic review to decide

Ruchika Sharma17 Feb 2024 2:16 PM IST

Drug major Novartis AG has announced a strategic review of Novartis India Ltd, a public company listed on the BSE.The strategic review will include an...

AstraZeneca collaborates with CSPC Pharma focused on AI-enabled research

AstraZeneca Tagrisso with chemotherapy approved in US for EGFR-mutated advanced lung cancer

Ruchika Sharma17 Feb 2024 12:00 PM IST

Tagrisso (osimertinib) is a third-generation, irreversible EGFR-TKI with proven clinical activity in NSCLC, including against CNS metastases.

Powered By: Hocalwire

X

We use cookies for analytics, advertising and to improve our site. You agree to our use of cookies by continuing to use our site. To know more, see our Cookie Policy and Cookie Settings.Ok